Provectus Biopharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €532.61K +10.7% -€4.08M +52.6% -766.9% -2.1 pp -€2.83M +27.7% -532.1% -0.71 pp
    €481.32K -43.6% -€2.68M -12.7% -556.2% -2.0 pp -€2.22M -15.4% -461.2% -1.5 pp
    €853.58K +∞% -€3.07M -35.8% -359.3% -3.6 pp -€2.62M +200.2% -307.5% -3.1 pp
    €0.00 +NaN% -€4.78M -17.0% N/A -€874.52K -75.2% N/A
    €0.00 +NaN% -€5.76M -3.5% N/A -€3.53M -34.0% N/A
    €0.00 +NaN% -€5.97M -15.1% N/A -€5.34M +18.9% N/A
    €0.00 +NaN% -€7.04M -39.7% N/A -€4.49M -49.6% N/A
    €0.00 +NaN% -€11.67M -44.7% N/A -€8.90M -53.0% N/A
    €0.00 +NaN% -€21.08M -0.3% N/A -€18.93M +26.0% N/A
    €0.00 -100.0% -€21.15M +139.2% N/A -€15.02M +26.3% N/A
    €3.61M +∞% -€8.84M -63.0% -245.2% -2.5 pp -€11.89M +39.4% -329.7% -3.3 pp
    €0.00 +NaN% -€23.90M +120.4% N/A -€8.53M -12.1% N/A
    €0.00 -100.0% -€10.85M -35.3% N/A -€9.70M -34.6% N/A
    €8.42B +∞% -€16.77M +4.8% -0.2% -0.0020 pp -€14.84M +25.2% -0.2% -0.0018 pp
    €0.00 +NaN% -€16.01M +50.6% N/A -€11.85M +59.8% N/A
    €0.00 +NaN% -€10.63M +20.0% N/A -€7.41M +20.6% N/A
    €0.00 +NaN% -€8.86M +2.6% N/A -€6.15M +22.3% N/A
    €0.00 -100.0% -€8.64M +12.8% N/A -€5.03M +36.9% N/A
    €1.18K -79.1% -€7.66M -24.6% -648,464.9% -4.7K pp -€3.67M +12.8% -310,858.6% -2.5K pp
    €5.64K -79.5% -€10.15M +170.7% -179,987.8% -1.7K pp -€3.25M +62.9% -57,674.3% -500 pp
    €27.49K +∞% -€3.75M +19.6% -13,640.8% -140 pp -€2.00M +52.7% -7,266.0% -73 pp
    €0.00 +NaN% -€3.13M -49.0% N/A -€1.31M +311.3% N/A
    €0.00 +NaN% -€6.15M +5,378.5% N/A -€318.13K -∞% N/A
    €0.00 -100.0% -€112.19K +1,030.4% N/A €0.00 +NaN% N/A
    €0.86 -€9.92K -1,150,000.0% €0.00 0.0%

    Notifications